{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(6)"],"submitter":["Canova S"],"funding":["AstraZeneca"],"pubmed_abstract":["<h4>Background</h4>Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate and few therapeutic options. After platinum-pemetrexed combination, no further promising drug seems to be effective. Immune checkpoint inhibitors may have some activity in pretreated patients and no data are available in this population about durvalumab.<h4>Materials and methods</h4>DIADEM was a multicenter, open-label, single-arm, phase II trial aimed at evaluating the efficacy and safety of durvalumab. Patients with locally advanced/metastatic MPM who progressed after platinum-pemetrexed chemotherapy were enrolled to receive durvalumab (1500 mg, intravenously Q4W) for 12 months or until evidence of disease progression or unacceptable toxicity. The primary endpoint was the proportion of patients"],"journal":["ESMO open"],"pagination":["100644"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9808442"],"repository":["biostudies-literature"],"pubmed_title":["Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma."],"pmcid":["PMC9808442"],"pubmed_authors":["Pagni F","Rulli E","D'Aveni A","De Vincenzo F","Mencoboni M","Cortinovis DL","Pasello G","Carlucci L","DIADEM groupD","Colonese F","Galli F","De Simone I","Bonomi M","Poli D","Torri V","D'Incalci M","Grosso F","Perrino M","Sala E","Sala L","Abbate MI","Ardizzoni A","Cortinovis D","Ceresoli GL","Santoro A","Canova S","Gelsomino F","Zucali PA","De Angelis A","Belletti M","Perez Gila M","Frega S","Bono F","Ugo F"],"additional_accession":[]},"is_claimable":false,"name":"Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.","description":"<h4>Background</h4>Malignant pleural mesothelioma (MPM) is a cancer with a high mortality rate and few therapeutic options. After platinum-pemetrexed combination, no further promising drug seems to be effective. Immune checkpoint inhibitors may have some activity in pretreated patients and no data are available in this population about durvalumab.<h4>Materials and methods</h4>DIADEM was a multicenter, open-label, single-arm, phase II trial aimed at evaluating the efficacy and safety of durvalumab. Patients with locally advanced/metastatic MPM who progressed after platinum-pemetrexed chemotherapy were enrolled to receive durvalumab (1500 mg, intravenously Q4W) for 12 months or until evidence of disease progression or unacceptable toxicity. The primary endpoint was the proportion of patients","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-05-28T03:41:34.561Z","creation":"2024-11-14T18:55:17.454Z"},"accession":"S-EPMC9808442","cross_references":{"pubmed":["36463732"],"doi":["10.1016/j.esmoop.2022.100644"]}}